NeoGenomics (NEO) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
NeoGenomics Reports 27% Revenue Growth Driven by Strong Volume Gains and PathLogic Acquisition
April 28, 2015 7:00 AM EDTFT. MYERS, Fla., April 28, 2015 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2015.
First Quarter 2015 Highlights:
Consolidated revenue growth of 27% Base(1) test volume growth of 28% Improvement in base average cost per test of 3.5% Adjusted EBITDA(2) of $1.5 millionRevenue for the first quarter was $23.0 million, a 27% increase over first quarter 2014 revenue. The PathLogic acquisition accounted for $2.3 million of revenue or 13% of this... More
